CEGEDIM
Cegedim Relationship Management today announced that Kyowa Pharmaceutical Industry Co., Ltd. has implemented Mobile Intelligence, the innovative Customer Relationship Management (CRM) solution designed exclusively for the Life Sciences industry. Kyowa selected the solution to boost the effectiveness of its sales force - promoting optimal interactions between sales representatives and Japan’s healthcare professionals (HCPs). Headquartered in Osaka, Kyowa Pharmaceutical is a member of the Lupin Group of India, and focuses its product portfolio on high-quality generics catered to psychiatric and neurological therapies.
Japan’s rapidly aging population is prompting the government to enact austerity measures that include a reliance on generic medications. This positions generic manufacturers for dynamic growth, and Kyowa is taking advantage of this opportunity. One of Kyowa’s tactics for enhancing commercial effectiveness during this critical time is to leverage a game-changing CRM optimized for the Life Sciences.
“Cegedim has a strong track record in CRM solutions for the Japanese pharmaceutical industry, and provides standardized templates based on proven expertise. Therefore, we evaluated that Cegedim’s solutions provide the necessary and sufficient functions for us,” said Mr. Noriaki Tsunoda, President and Representative Director, Kyowa Pharmaceutical Industry Co., Ltd. “Also, it was an important part of our decision that the Cegedim implementation team has extensive knowledge about the pharmaceutical industry. Cegedim understands our sales strategy well, and with their tablet offering and cloud-based architecture, we have the flexibility and security to empower our sales force with on-the-go accessibility. We are confident that the system will be an intelligent infrastructure. Furthermore, we can accelerate intelligence sharing between the sales force and the back-office. We expect that this will bring our organization agility (as our slogan “One Team”), and will help us take full advantage of business opportunities. We believe Mobile Intelligence will become our indispensable key weapon for our growth strategy. Although market transformation and tough competition will happen in the future, we expect that Cegedim will continue to provide leading solutions for generic pharmaceutical companies, and help them improve.”
“It’s inspiring to help Kyowa capitalize on this unique growth opportunity. Mobile Intelligence empowers the enterprise to elevate efficiency, not only for members of commercial teams, but also back-end divisions that are enabled with the ability to enhance governance and strategy execution,” said Stefan Janssens, President EMEA & APAC, Cegedim Relationship Management. “Building on their 60-year legacy in the Life Sciences, we’re expecting to propel Kyowa on a path of continued prosperity with our innovative, next generation CRM.”
|
About
|
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables approximately 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group. To learn more, please visit: www.CegedimRM.com . Follow Cegedim Relationship Management on LinkedIn and Twitter . |
|||
|
About
|
Founded in 1969, Cegedim is a global technology and services
company specializing in the healthcare field. Cegedim supplies
services, technological tools, specialized software, data flow
management services and databases. Its offerings are targeted
notably at healthcare industries, life sciences companies,
healthcare professionals and insurance companies. The world leader
in life sciences CRM, Cegedim is also one of the leading suppliers
of strategic healthcare industry data. Cegedim employs 8,000
people in more than 80 countries and generated revenue of €902
million in 2013. Cegedim SA is listed in Paris (EURONEXT: CGM). Follow Cegedim on Twitter: @CegedimGroup . |
|||
Contact:
Drew BUSTOS
Cegedim Relationship Management
Global
Communications
Tel.: +1 (908) 443.2451
drew.bustos@cegedim.com
or
Aude
BALLEYDIER
Cegedim
Media Relations
Tel.: +33 (0)1 49
09 68 81
aude.balleydier@cegedim.fr
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 15:00:00 CEST | Press release
The brand brings its high-performance, clinically proven, nature-inspired skincare to Amazon shoppers Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy a
The smarter E Europe 2025: Studies, Technologies and Market Trends for the Energy System of Tomorrow16.5.2025 12:47:00 CEST | Press release
Exactly one week has passed since The smarter E Europe closed its doors in Munich. Once again, Europe’s largest alliance of exhibitions for the energy industry turned the Bavarian capital into the epicenter of the global energy sector and impressed with outstanding results. Over the course of three days, 2,737 exhibitors from 57 countries showcased their technologies, business models and market-ready solutions for an intelligent, interconnected and fully renewable energy system. Around 107,000 professionals from 157 nations took the opportunity to connect, initiate partnerships and launch new projects. The accompanying conferences and side events also attracted strong interest, drawing more than 2,600 participants. The message sent out by The smarter E Europe and its four exhibitions – Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe – was clear: We are the energy system. This press release features multimedia. View the full release here: https://www.businesswire.c
IFF Announces Early Tender Results and Increase of Tender Offers for Certain Outstanding Series of Notes16.5.2025 12:30:00 CEST | Press release
IFF (NYSE: IFF) announced today the early tender results for its tender offers to purchase for cash certain of its outstanding series of Notes. IFF also announced it has increased the previously announced Pool 1 Maximum Amount (as defined below) from $1,000,000,000 to $1,100,000,000 (the “Amended Pool 1 Maximum Amount”), the Pool 2 Maximum Amount (as defined below) from $800,000,000 to $900,000,000 (the “Amended Pool 2 Maximum Amount”, and together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), the 2027 Series Tender Cap (as defined below) from $300,000,000 to $400,000,000 and the 2050 Series Tender Cap (as defined below) from $600,000,000 to $649,114,000. The 2025 Notes Series Tender Cap and the 2040 Notes Series Tender Cap (each as defined below) remain unchanged at $500,000,000 and $450,000,000, respectively. Details of tender offers IFF initially offered to purchase for cash: (i) up to $1,000,000,000 aggregate purchase price, excluding accrued and unpaid in
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum